#United States #New York #Verint #Metsera #First Savings

Investigation of Shareholder Rights

Halper Sadeh LLC, a well-known firm specializing in investor rights, has recently begun investigations into several companies over concerns regarding potential violations of federal securities laws and breaches of fiduciary duties to their shareholders. This inquiry notably includes an analysis of First Savings Financial Group, Inc. (NASDAQ FSFG), Metsera, Inc. (NASDAQ MTSR), Verint Systems Inc. (NASDAQ VRNT), and Merus N.V. (NASDAQ MRUS).

First Savings Financial Group, Inc. (FSFG)

The firm is particularly concerned with FSFG's proposed sale to First Merchants Corporation. Under the current terms, shareholders of FSFG stand to receive only 0.85 shares of First Merchants common stock for each share of First Savings stock they own. This valuation decision has raised concerns among investors regarding its fairness and whether it adequately compensates them for their stakes in the company. Halper Sadeh LLC is urging FSFG shareholders to explore their legal options alongside the ongoing investigation.

Metsera, Inc. (MTSR)

Similarly, Halper Sadeh LLC is investigating Metsera due to its planned acquisition by Pfizer Inc. The deal stipulates that Metsera shareholders will receive $47.50 per share at closing, with additional contingent rights that could yield up to $22.50 per share, contingent on certain clinical and regulatory milestones being met. The firm is evaluating whether the proposed payout is beneficial enough for shareholders, especially given the possible future value associated with those contingent rights.

Verint Systems Inc. (VRNT)

The case of Verint Systems is also under scrutiny as the company has agreed to a sale to Thoma Bravo for $20.50 per share in cash. Shareholders are advised to reach out to Halper Sadeh LLC to ascertain if this offer maximizes their equity and potential gains from their investment in Verint.

Merus N.V. (MRUS)

Finally, Merus is involved in an acquisition where the prospective buyer, Genmab A/S, has proposed a purchase price of $97.00 per share. The investigation aims to determine whether this acquisition offers an adequate reflection of Merus's actual market value and prospects going forward.

Actions for Shareholders

Halper Sadeh LLC is committed to seeking improved offers for shareholders, greater transparency in the transactions, and exploring other avenues of relief and benefits. Importantly, the firm operates on a contingency fee basis, meaning shareholders will not incur any out-of-pocket costs for legal fees unless the case is won.

Interested shareholders are encouraged to communicate with the firm at no charge to discuss their rights and options moving forward. For inquiries, they can contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].

Conclusion

Halper Sadeh LLC has a longstanding track record of advocating for investors worldwide. They aim to rectify instances of securities fraud and corporate mismanagement, helping clients recover funds and enact reforms within companies. The firm invites shareholders affected by these proposed transactions to engage in the investigation process to safeguard their rights and ensure they receive fair treatment during these significant changes in ownership.